Pinned post
Thank you to @CBSNews for highlighting our #research!
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
What if doctors could test cancer treatments on your tumor, without putting a single one of those treatments into your body? CBS News’ Riley Callanan reports.View quoted post on X
